Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer Sells Prescription Derm Unit - Happi
Company News

Bayer Sells Prescription Derm Unit

DENMARK/GERMANY: Bayer is selling its global prescription dermatology unit to Leo Pharma. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids with an annual turnover in 2017 of more than €280 million (about $318 million at current exchange rates).  The transaction does not include Bayer’s OTC dermatology portfolio of brands such as Bepanthen and Canesten among others.

Leo Pharma will acquire the global product rights, except for Afghanistan and Pakistan, and take over the sales and marketing organizations in 14 countries, as well as a factory in Segrate, Italy.

The acquisition is expected to close in two steps; during 2018 for the US, and during the second half of 2019 for all other markets, subject to the satisfaction of customary closing conditions, including approval by the competition authorities.
Financial details of the transaction were not disclosed. 

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters